Exagen Inc Q3 2024 Earnings Revenue Misses Estimates at 12.5M, Net Loss Narrows to 5.0M
| XGN Stock | USD 3.97 0.13 3.39% |
About 54% of Exagen's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Exagen Inc suggests that some traders are interested. Exagen's investing sentiment overview a quick insight into current market opportunities from investing in Exagen Inc. Many technical investors use Exagen Inc stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Exagen |
Revenue Reported at 12.5 million for Q3 2024, falling short of the analyst estimate of 13.57 million, impacted by 1.2 million in one-time adjustments.Net L
Read at gurufocus.com
 |
Exagen Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Exagen can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Exagen Fundamental Analysis
We analyze Exagen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exagen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exagen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Exagen is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Exagen Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Exagen stock to make a market-neutral strategy. Peer analysis of Exagen could also be used in its relative valuation, which is a method of valuing Exagen by comparing valuation metrics with similar companies.
Peers
Exagen Related Equities
| BNR | Burning Rock | 16.01 | ||||
| DRIO | DarioHealth Corp | 9.72 | ||||
| SERA | Sera Prognostics | 1.81 | ||||
| BDSX | Biodesix | 0.70 | ||||
| SHC | Sotera Health | 0.53 | ||||
| FONR | Fonar | 0.49 | ||||
| PMD | Psychemedics | 0.43 | ||||
| CSTL | Castle Biosciences | 0.53 |
Check out Exagen Hype Analysis, Exagen Correlation and Exagen Performance. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 3.163 | Quarterly Revenue Growth 0.066 | Return On Assets (0.17) | Return On Equity (0.70) |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.